Lipocine Inc. has received Health Canada approval for TLANDO, marking a significant advancement in testosterone replacement therapy for men suffering from low testosterone levels.

Descriptive, non-directional summary of recent AI analyses.

Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.

Reported Wednesday, Oct 7 - 8:05am EDT (TheFly subscription required to read more.)

Lipocine and BLOOM: the next postpartum depression trial, prior Phase 3 results, cash use, TLANDO royalties and share dilution, with dated sources.

Lipocine (NASDAQ: LPCN) reported second quarter 2026 net loss of $2.6 million, or $0.32 per diluted share, versus a $2.2 million loss a year earlier. Total Q2 revenue was $190,099, down from $622,849, reflecting absence of $500,000 in prior-year license revenue, while TLANDO royalty revenue increased to $190,099 from $122,849.As of June 30, 2026, Lipocine held $23.3 million in unrestricted cash, cash equivalents and marketable securities, up from $14.9 million at year-end 2025. The Phase 3 trial of LPCN 1154 (Brlizio) in postpartum depression did not meet its primary endpoint, but a post hoc analysis excluding one outlier site suggested rapid, sustained symptom improvement. Lipocine has initiated a new placebo-controlled PPD trial, scheduled an FDA guidance meeting for Q3 2026, is planning Phase 2 protocols for LPCN 2201 (MDD) and LPCN 2203 (essential tremor), and reported UAE marketing authorization for TESTYRA (TLANDO) via partner Pharmalink.

Reported Monday, Jun 9 - 8:10am EDT (TheFly subscription required to read more.)

Lipocine Inc. has released its financial results for Q1 2026, highlighting LPCN 1154's clinical trial outcomes and ongoing partnerships as it navigates future developments.

Lipocine Inc. shared its financial results for 2025, showcasing significant pipeline developments for mental health and metabolic disorders, setting the stage for future progress.

Lipocine Inc. announces third quarter financial results for 2025 and updates on clinical trials, including LPCN 1154 for postpartum depression.

Lipocine Inc. shares Q2 financial results and advancements on LPCN 1154, a treatment for postpartum depression, alongside updates on LPCN 2401.

Lipocine Inc. announces a New Drug Submission for TLANDO® in Canada, aiming to meet the growing demand for testosterone replacement therapy.

Lipocine Inc. will present its advanced drug delivery technology at A.G.P.'s Annual Healthcare Company Showcase on May 21, 2025, highlighting promising therapeutic candidates.

Lipocine Inc. announces its financial performance for Q1 2025, highlighting key developments and ongoing studies towards innovative treatments.

Lipocine Inc. announces a new licensing agreement with Aché for TLANDO®, a testosterone therapy, aimed at tapping into Brazil's growing market for prescription testosterone products.

Cash and securities rose to $24.7M from $14.9M at year-end, while TLANDO royalties reached $119,000. Lipocine awaits FDA feedback on LPCN 1154.

Novel oral testosterone therapy targets 700K annual prescriptions in Canada. First-in-class treatment requires no dose adjustment. Learn expansion timeline.

Lipocine partners with Aché for TLANDO in Brazil's fast-growing testosterone market. First oral therapy potential, 34% CAGR opportunity. See deal terms.